ALBUMIN FUSION TECHNOLOGY EXTENDS FACTOR IX TIME IN CIRCULATION

Albumin is a naturally occurring protein that was specifically selected for its prolonged half‑life

Recombinant albumin IDELVION is formed by fusing recombinant albumin, known for its long half-life and low risk for immunogenic reaction, with recombinant Factor IX (rFIX).

Cleavable peptide linker Upon initiation of the coagulation cascade, recombinant albumin is cleaved, only releasing activated Factor IX (FIX) when needed for coagulation.

rFIX The rFIX remains linked to the recombinant albumin via a cleavable peptide linker so it remains inactive until it’s needed to control a bleed.

MOA molecule
  • 1

    Recombinant albumin IDELVION is formed by fusing recombinant albumin, known for its long half-life and low risk for immunogenic reaction, with recombinant Factor IX (rFIX).

  • 2

    Cleavable peptide linker Upon initiation of the coagulation cascade, recombinant albumin is cleaved, only releasing activated Factor IX (FIX) when needed for coagulation.

  • 3

    rFIX The rFIX remains linked to the recombinant albumin via a cleavable peptide linker so it remains inactive until it’s needed to control a bleed.

Up to 14-day dosing (FDA approved)

Dosing schedule that meets your patients’ needs

VIEW FULL DOSING INFORMATION
0 spontaneous bleeds

IDELVION is the only extended half-life Factor IX therapy to deliver a zero median annualized spontaneous bleeding rate when dosed at 7 or 14 days in clinical trials

VIEW EFFICACY DATA
X
You are now leaving the current website.

Do you want to continue?